Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**Financial Risk Summary: Medicamen Biotech Limited** The company faces critical **compliance risk** (10.0/10 score) with potential SEBI enforcement action and delisting exposure if BRSR Core Expansion disclosures are not met—a material threat to market access for a ₹151.5 crore revenue company. **EPR (Extended Producer Responsibility) exposure remains unquantified** at 6.5/10 risk level; pharmaceutical packaging waste obligations under the Plastic Waste Management Rules 2021 could trigger unforeseen liabilities if the EPR applicability status is not clarified and actioned immediately. The estimated compliance cost of ₹0–1 crore is likely understated given missing emissions baseline data (Scope 1 and 2 both reported as zero), which suggests incomplete environmental accounting rather than genuine zero emissions—this creates audit and regulatory credibility risk. Immediate priorities: clarify EPR registration status, conduct comprehensive emissions inventory using SEBI-mandated GHG protocols, and establish compliance governance to avoid enforcement action.
Source: Medicamen Biotech Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.